Drug Profile
Research programme: neurodegenerative disorders antibody therapeutics - Prothena/Celgene
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Prothena
- Developer Celgene Corporation; Prothena
- Class Antibodies; Neuroprotectants
- Mechanism of Action Protein folding modulators; TDP-43 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders